However, it is today necessary for oncologists carefully to consider NAT in early breast cancer patients, mainly in HER2+ and in triple negative subtypes, according to ESMO and AIOM guidelines, because NAT also allows the assessment of response to therapy, which has an established prognostic value and may guide the choice of post-operative treatment. The gene discussed is ERBB2; the disease is breast cancer.